ArticleJournal of affective disorders2018
Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.
Article in Journal of affective disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Reduced nucleus accumbens functional connectivity in reward network and default mode network in patients with recurrent major depressive disorder.Translational psychiatry · 2022Pooled it
- Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.Journal of affective disorders · 2025Trial
- Thyroid dysfunction and Research Domain Criteria framework-based depression phenotypes: Insights from a historical longitudinal cohort.Journal of affective disorders · 2026Article
- Editorial: Recognizing Atypical Depression in Youth: Advancing Precision Diagnosis.Journal of the American Academy of Child and Adolescent Psychiatry · 2026Article
- Aberrant dynamic functional architecture in major depressive disorder: Vertex-Wise large-sample fMRI analyses reveal network-specific alterations and symptom associations.Translational psychiatry · 2026Article
- The METOD study: exploring metabolism, emotional blunting and treatment outcomes in depression - A naturalistic, two-phase observational protocol.Frontiers in pharmacology · 2026Article
- Neuroanatomical dimensions in major depression linked to cognition, adverse life events, self-harm, metabolomics and genetics.Communications medicine · 2025Article
- Elucidating Development Trajectories of Brain Functional Abnormalities in Major Depressive Disorder Utilizing a Data-Driven Disease Progression Model.Human brain mapping · 2025Article
- Road Map to Better Depression Care: A Road No Longer Less Traveled.Focus (American Psychiatric Publishing) · 2025Article
- Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior.Psychological medicine · 2023Article
- Associations of Prenatal Chemical and Nonchemical Stressors with Early-Adulthood Anxiety and Depressive Symptoms.Environmental health perspectives · 2023Article
- Transdiagnostic biomarker approaches to mental health disorders: Consideration of symptom complexity, comorbidity and context.Brain, behavior, & immunity - health · 2021Article
- Resting State Functional Connectivity Biomarkers of Treatment Response in Mood Disorders: A Review.Frontiers in psychiatry · 2021Review
- Invasive Electrophysiology for Circuit Discovery and Study of Comorbid Psychiatric Disorders in Patients With Epilepsy: Challenges, Opportunities, and Novel Technologies.Frontiers in human neuroscience · 2021Article
- A transdiagnostic approach to conceptualizing depression across the perinatal period in a high-risk sample.Journal of abnormal psychology · 2020Observational
- Article
- Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression.Journal of affective disorders · 2020Article
- Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.Journal of affective disorders · 2020Article
- Reduced default mode network functional connectivity in patients with recurrent major depressive disorder.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC).Innovations in clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundSubstantial research progress can be achieved if available clinical datasets can be mapped to the National Institute of Mental Health Research-Domain-Criteria (RDoC) constructs. This mapping would allow investigators to both explore more narrowly defined clinical phenotypes and the relationship of these phenotypes to biological markers and clinical outcomes approximating RDoC criteria.
methodsUsing expert review and consensus, we defined four major depression phenotypes based on specific RDoC constructs. Having matched these constructs to individual items from the Hamilton Depression Rating Scale and Quick Inventory of Depressive Symptomatology, we identified subjects meeting criteria for each of these phenotypes from two large clinical trials of patients treated for major depression. In a post hoc analysis, we evaluated the overall treatment response based on the phenotypes: Core Depression (CD), Anxiety (ANX), and Neurovegetative Symptoms of Melancholia (NVSM) and Atypical Depression (NVSAD).
resultsThe phenotypes were prevalent (range 10.5-52.4%, 50% reduction range 51.9-82.9%) and tracked with overall treatment response. Although the CD phenotype was associated with lower rates of remission in both cohorts, this was mainly driven by baseline symptom severity. However, when controlling for baseline severity, patients with the ANX phenotype had a significantly lower rate of remission. LIMITATIONS: The lack of replication between the studies of the phenotypes' treatment prediction value reflects important variability across studies that may limit generalizability.
conclusionFurther work evaluating biological markers associated with these phenotypes is needed for further RDoC concept development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.